The development history of Guoyitang
Since the implementation of GMP, GSP and GAP certification in my country’s pharmaceutical industry, pharmaceutical companies have encountered unprecedented development opportunities. At the same time, they have also faced huge technical challenges and varieties. Pressure to update. Management regulations, market environment and corporate status quo have prompted Guoyitang Holdings to continue to invest, increase expansion and reform efforts, combine the research and development of new drugs and special drugs, the planting, breeding, processing and marketing of local medicinal animals and plants, and use science and technology to develop enterprises and integrate Capital market road, in order to establish new profit growth points and ensure the long-term prosperity and sustainable development of enterprises.
Guoyitang Pharmaceutical has a reasonable asset structure and clear development goals. As early as 2003, the cumulative investment in new construction and technical renovation in the early stage has reached more than 45 million yuan, with 18,861 square meters of new factory buildings and supporting buildings, and 233 new sets of production and quality control equipment for the four dosage forms of tablets, pills, capsules and granules. , implemented and passed the GMP transformation and ISO9001 national certification and acceptance, developed, introduced, and reserved 192 varieties of new and special drugs, including 10 nationally protected varieties of traditional Chinese medicine.
Chinese medicinal materials are the basis for preparing Chinese medicine pieces; Chinese medicine pieces are an important link in the production of Chinese medicine preparations; the stability of Chinese medicine quality depends on the quality of the pieces. Guoyitang Pharmaceutical has long produced a large number of various types of Chinese patent medicines and is deeply aware of the impact of uneven quality of medicinal materials on the quality of Chinese medicines. There has been no unified standard for the production of Chinese herbal medicines and Chinese herbal pieces in China for a long time. To this end, the State Food and Drug Administration requires GMP transformation and certification for the production of traditional Chinese medicine pieces, which will ensure the quality of traditional Chinese medicines. Guoyitang Pharmaceutical's Guangdong production base has a very superior climate, geography and environment, which is very suitable for the production of real estate medicinal materials. After many inspections and demonstrations by traditional Chinese medicine experts, it is recommended to give full play to local advantages and use precious geothermal resources to carry out the planting, breeding and processing of traditional Chinese medicines and establish a unique medicine source base. With the support of the local government, the first batch of 200 acres of provenance base has been approved by the government for purchase. To this end, it jointly invested with the National Traditional Chinese Medicine Group to establish Guangdong Guoyitang Medicinal Source Base Co., Ltd., and worked closely with the local drug regulatory and agricultural authorities. The management departments jointly promote the industrialized management of Chinese herbal medicines, which will contribute to exploring and formulating unified standards for the production of Chinese herbal medicines and Chinese herbal pieces, ensuring the quality of Chinese medicines and increasing the income of local farmers. Guoyitang Pharmaceutical obtained the qualification for the production and labeling of the first batch of traditional Chinese medicine pieces from the State Food and Drug Administration in 2003. The close integration of medicine source bases and traditional Chinese medicine pieces has formed the industrial chain of Guoyitang Pharmaceutical, achieving a win-win situation for social benefits and enterprise development.
In the process of corporate restructuring, Guoyitang Pharmaceutical has been increasing the progress of corporate restructuring and expansion. From the second phase of the technical transformation project implemented in early 2005, an investment of 25 million yuan (of which nearly 10 million yuan was invested in the research and development of new and special drugs), the development and introduction of soft capsules, eye drops, ointments, gels, sprays, liniments, etc. 60 varieties of new dosage forms are expected to be completed in August 2006. Immediately afterwards, the third phase of the technical transformation project was implemented, with an investment of 20 million yuan (of which more than 7 million yuan was invested in the research and development of new drugs and special drugs), and 22 new dosage forms of powder injection and large infusion were developed and introduced; at the same time, the production scale of tablets and pills was expanded. After the completion of the third phase of the technical transformation project, more than 270 varieties of 13 dosage forms have been formed, including categories 5, 6, 8, and 9 of traditional Chinese medicines and categories 3, 4, 5, and 6 of chemical drugs. In terms of hardware scale and software reserves, it ranks among the advanced ranks in the country. So far, Guoyitang Holdings has invested a total of more than 90 million yuan in reform and expansion funds, achieving the short-term development goals of Guoyitang Pharmaceutical.
The research, development and introduction of drugs are the lifeblood of pharmaceutical companies. Guoyitang Holdings sincerely invites a backbone R&D team with top-notch academics, leading technology, strong sense of responsibility, and sincere unity. They have been engaged in drug research for a long time and have a wide range of research topics. They have good information on new drugs, specialty drugs, and generic drugs. They have rich technical experience and profound professional knowledge. They are experts and scholars who are familiar with the development trends of the domestic and foreign pharmaceutical industries. Among them, full-time R&D personnel 19 (5 senior, 6 deputy senior, 8 intermediate) and 15 part-time medical experts (8 senior, 6 deputy senior, 1 intermediate). To this end, the Beijing Institute of Traditional Chinese Medicine has been established with capital injection, and has established close collaborative relationships with the state, professional colleges and scientific research institutions in Beijing and Guangzhou, and formed a research and development team with wide information sources, high professional level, and flexible and effective management. Provide products and technical services to enterprises, specializing in medicinal chemistry, pharmaceutical preparations, pharmaceutical analysis, pharmacology and toxicology, clinical research and other fields.
This enables Guoyitang Pharmaceutical to complete practical work such as extraction, separation, purification, preparation and analysis of natural drugs, registration, evaluation of drug effectiveness and safety, and pilot scale-up of natural drugs with high efficiency and high quality. It has reserved a large number of new products of common drugs and special drugs, and obtained exclusive It has 5 patented technologies and successfully registered 99 trademarks of traditional Chinese medicine and health products, laying a technical foundation for the realization of technological enterprise and sustainable development. Under the overall plan of the Beijing Institute of Traditional Chinese Medicine, Guangdong Guoyitang Pharmaceutical Co., Ltd. has built and used a drug analysis laboratory, a natural medicine laboratory, a preparation research laboratory, a biochemical drug laboratory, a pharmacology and toxicology laboratory, and a Chinese medicine laboratory since 2003. The laboratory is equipped with advanced equipment including new HPLC, and combines new product development, introduction and product brand building, and has strong new product development capabilities and quality assurance systems.
Looking to the future, there is a long way to go.
When Guoyitang Pharmaceutical achieves stock issuance and listing and integrates into the capital market, Guoyitang Pharmaceutical's medium and long-term strategic goals and the expectations of investors will be realized in a healthy and orderly manner. Let us work together to achieve her growth and glory!